Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 1 - Studien 1 bis 10 von insgesamt 78
- Rekrutierung läuftA Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination withCheckpoint Inhibition for the Treatment of Participants with Relapsed or RefractoryMultiple Myeloma
- Rekrutierung läuft
ADOREG - Bundesweites prospektives Register zur Versorgungsforschung in der dermatologischen Onkologie
- Rekrutierung läuftA phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapyMolekulare Marker
- Rekrutierung läuftA Prospective Multicenter Phase 2 Study of the Chemotherapy-Free Combination of the Intravenous Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Copanlisib in Combination with Obinutuzumab in Patients with Previously Untreated Follicular Lymphoma (FL) and a High Tumor Burden.Molekulare Marker
- Rekrutierung läuftSpendervermittelte B-Zell Immunität gegen tumorassoziierte Autoantigene als Grundlage von Graft-versus-Leukämie-Effekten in der allogenen Stammzelltransplantation
- Rekrutierung läuftCAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIb AL Amyloidosis
- Rekrutierung läuftCAELUM Cardiac Amyloid Reaching for Extended Survival A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis
- Rekrutierung läuft
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy (PAVO)
Molekulare Marker - Rekrutierung läuft
A phase I/IIa clinical trial to assess feasibility, safety and antitumor activity of autologous SLAMF7 CAR-T cells in multiple myeloma
Molekulare Marker - Rekrutierung läuftA Phase 2, Multicohort Open-Label study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy directed against BCMA in Subjects with Multiple Myeloma (68284528MMY2003)Molekulare Marker